Illumina's Stock Jumps 16 Percent on Affy Settlement | GenomeWeb
NEW YORK (GenomeWeb News) - Illumina’s stock rose nearly 16 percent, to $70.02, in afternoon trading after this morning’s news that the company will settle its longstanding patent-infringement litigation with Affymetrix without admitting liability and without paying royalties.
 
Under the terms of the settlement, Illumina will pay Affy $90 million and the companies agreed to a covenant not to sue each other in the future.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.